Search details
1.
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Int J Mol Sci
; 25(9)2024 Apr 26.
Article
in English
| MEDLINE | ID: mdl-38731936
2.
Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.
Haematologica
; 102(1): 168-175, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27540138
3.
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Haematologica
; 102(12): 2113-2124, 2017 12.
Article
in English
| MEDLINE | ID: mdl-28860344
4.
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.
Blood
; 122(22): 3591-8, 2013 Nov 21.
Article
in English
| MEDLINE | ID: mdl-24072855
5.
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Haematologica
; 105(3): e116-e120, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31320555
6.
Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication.
Haematologica
; 98(4): 640-8, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23100276
7.
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.
Haematologica
; 97(7): 1110-4, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-22315496
8.
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
Haematologica
; 96(5): 687-95, 2011 May.
Article
in English
| MEDLINE | ID: mdl-21330323
9.
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression.
Cancers (Basel)
; 13(6)2021 Mar 17.
Article
in English
| MEDLINE | ID: mdl-33802806
10.
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Cells
; 10(3)2021 03 04.
Article
in English
| MEDLINE | ID: mdl-33806619
11.
Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.
Cancers (Basel)
; 12(10)2020 Sep 24.
Article
in English
| MEDLINE | ID: mdl-32987735
12.
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial.
Cancers (Basel)
; 12(12)2020 Dec 03.
Article
in English
| MEDLINE | ID: mdl-33287189
13.
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.
Cells
; 8(11)2019 11 13.
Article
in English
| MEDLINE | ID: mdl-31766279
14.
Reply to "Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-1114.
Haematologica
; 98(1): e10, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23397607
15.
Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.
Clin Cancer Res
; 23(21): 6602-6615, 2017 Nov 01.
Article
in English
| MEDLINE | ID: mdl-28790111
16.
The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Clin Cancer Res
; 23(1): 225-238, 2017 Jan 01.
Article
in English
| MEDLINE | ID: mdl-27440267
17.
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
J Hematol Oncol
; 10(1): 127, 2017 06 20.
Article
in English
| MEDLINE | ID: mdl-28633670
18.
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
PLoS One
; 9(3): e92378, 2014.
Article
in English
| MEDLINE | ID: mdl-24658332
19.
Inhibition of ATP-sensitive potassium channels increases HSV-tk/GCV bystander effect in U373 human glioma cells by enhancing gap junctional intercellular communication.
Neuropharmacology
; 59(6): 480-91, 2010 Nov.
Article
in English
| MEDLINE | ID: mdl-20603136
20.
Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up-regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation.
Glia
; 54(2): 125-34, 2006 Aug 01.
Article
in English
| MEDLINE | ID: mdl-16718685
Results
1 -
20
de 20
1
Next >
>>